WASHINGTON
Squinting at the menu? Holding your phone at arm's length? Perching a pair of cheap drugstore readers on your head and losing them for the fifth time this week? On Friday, the US Food and Drug Administration handed the 45-and-over crowd something new to think about: a prescription eye drop designed to bring close-up text back into focus without lenses.
The agency approved phentolamine ophthalmic solution 0.75%, sold as RYZUMVI, for the treatment of presbyopia in adults. The announcement came on 16 October from Opus Genetics, the clinical-stage biotech that developed the drug, and its commercial partner Viatris, which holds exclusive US commercialisation rights under a global licensing agreement. The drug was already approved in the US for reversing pharmacologically induced pupil dilation; the new approval opens the door to a vastly bigger audience.
Opus Genetics says presbyopia affects about 90 percent of US adults over 45. That is tens of millions of people — and a very large market.
What Is Presbyopia, Anyway?
Presbyopia is the gradual, universal loss of near focus that arrives with age, typically becoming noticeable in the early-to-mid 40s. The lens inside the eye stiffens, and the eye struggles to refocus from distance to reading range. It is not a disease so much as a rite of passage — and for generations the only fixes have been reading glasses, bifocals, multifocal contact lenses or surgery.
Eye drops have been promised as an alternative for years, and the first one arrived in 2021 with Vuity, a pilocarpine-based drop. Qlosi, another pilocarpine product, was approved in October 2023 and launched commercially in April 2025. A lower-cost generic version of Vuity reached pharmacies in August 2025, and GoodRx lists prices as low as about $26.50 at some pharmacies for the generic, with Qlosi available for as little as $79 through certain mail-order pharmacies with a manufacturer savings offer.
A Different Kind of Drop
What makes RYZUMVI interesting is how it works. Vuity and Qlosi use pilocarpine, which constricts the pupil by stimulating muscles in the eye. Phentolamine takes the opposite route: it is a non-selective alpha-1 and alpha-2 adrenergic antagonist that blocks the signal telling the iris's dilator muscle to open. The pupil shrinks, and the eye's depth of focus increases — the same optical trick as a pinhole camera — without engaging the ciliary muscle, the focusing muscle inside the eye.
Opus Genetics describes the product as a preservative-free eye drop. That matters to people with sensitive eyes: Vuity contains the preservative benzalkonium chloride, while Qlosi, like RYZUMVI, is preservative-free.
The Numbers: What the Trials Showed
The approval rests on two pivotal Phase 3 studies, VEGA-2 and VEGA-3, both of which the company says met their primary and all key secondary efficacy endpoints. The detail is in VEGA-3, a randomised, double-masked, placebo-controlled study at 40 US sites that enrolled 545 participants split 3 to 2 between drug and placebo. Patients dosed once daily, in the evening.
The primary goal was demanding: gaining at least 15 letters — three lines on a standard eye chart — in near vision while losing fewer than five letters of distance vision, measured 12 hours after dosing on day 8. 27.2 percent of people on phentolamine hit that mark, versus 11.5 percent on placebo (p<0.0001). Even one hour after the very first dose on day 1, 20.6 percent of drug recipients achieved the three-line gain compared with 6.1 percent on placebo.
The company reports no tachyphylaxis — the fading of a drug's effect with repeated use — over six weeks relative to day 8, and patient-reported outcomes favoured the drug at days 3 and 8 and at six weeks. The VEGA-3 protocol also includes 48 weeks of long-term safety monitoring. Opus says there were no treatment-related serious adverse events.
The Catch: Side Effects and Caveats
Nothing about this is magic. Fewer than three in ten people in the trial hit the demanding main target, and the top-line result is that about 27 percent responded versus 11.5 percent on placebo. That does not mean everyone else saw nothing — the target was a strict three-line gain — but it does mean that for many users the drops may deliver a modest, partial benefit. Expect your results to vary.
It is also worth remembering what the trials did not tell us. VEGA-3 followed patients for six weeks of efficacy testing, with a longer 48-week safety follow-up built into the protocol, so real-world, years-long experience simply does not exist yet. Questions about how the drops perform in people with unusual pupils, in different lighting, or alongside other eye medications will only be answered once the product is on the market and doctors start reporting what they see. The press materials describe no treatment-related serious adverse events, but experienced ophthalmologists know that rarer problems tend to surface only after thousands of patients have used a product.
The most common side effects in the presbyopia studies were conjunctival hyperemia — plain old red eye — in 21 percent of patients and irritation at the instillation site in 16 percent. In the earlier mydriasis indication, instillation-site discomfort (16 percent), red eye (12 percent) and dysgeusia, a funny taste in the mouth (6 percent), were the most common reactions. Headache occurred in 2.6 percent in VEGA-3. The company says most reactions were mild, transient and resolved on their own.
The label carries sensible warnings. The drops are not recommended for people with active eye inflammation such as iritis. Users should avoid touching the vial tip to the eye or any surface. Contact lens wearers must remove their lenses before dosing and wait 10 minutes before putting them back.
What the Experts Say
Eye doctors are cautiously interested rather than wildly excited. Alice Epitropoulos, MD, sees such drops as an adjunct rather than a replacement for glasses or contacts, and urges caution in patients with higher uncorrected farsightedness, more advanced presbyopia, or meaningful dry eye and ocular surface disease. John Hovanesian, MD, has pointed out that earlier presbyopia drugs have met limited enthusiasm from both doctors and patients, observing that "doctors debate, but patients decide" — and that trial results only partly predict commercial success.
There is also a business story. For Opus Genetics, which is primarily developing gene therapies for inherited retinal diseases through seven AAV-based programmes, this is its second US drug approval, and the approval triggers a milestone payment. CEO George Magrath, MD, called it "an important milestone for Opus Genetics." One report notes Viatris's strategy for the expanded label is still being evaluated, and neither pricing nor a launch date has been announced, so practices will need to confirm availability directly.
RYZUMVI vs. the Rivals
For consumers the big question is whether to ask for this instead of — or alongside — the pilocarpine drops. Pilocarpine products are already on the market, with cheap generics, and come with their own caveats: redness, watery eyes, vision impairment, and rare reports of retinal tears and detachments with Vuity that lead to recommendations for a retinal exam before starting. Phentolamine acts through a different mechanism, which may suit some patients better, but there are no head-to-head trials yet, so no one can honestly say which is superior.
Cost will likely decide much of this. Reading glasses cost a few dollars; generic Vuity can be found for under $30 in some places. A brand-new branded drop will need to justify a premium, and insurers rarely cover treatments for a condition they regard as a normal part of ageing.
What This Means For You
If you are over 40 and tired of your readers, it is worth raising with an optometrist or ophthalmologist at your next visit. A proper eye exam is the starting point: your doctor can check that your blurry near vision is simply presbyopia and not something more serious like cataracts, dry eye or retinal problems, and can tell you whether you are a good candidate. People with active eye inflammation, significant dry eye or advanced presbyopia may be steered away.
Think about how you live. The drops work by narrowing the pupil, so users of existing products commonly report dimmer vision in low light; if you drive a lot at night or work in dim environments, discuss that with your doctor. Do not stop wearing your glasses on your own and do not share drops. If you have any sudden flashes of light, floaters or a curtain over your vision, seek urgent care regardless of what you are using.
And be realistic. This is a prescription treatment that helps some people see closer text more clearly for part of the day, not a cure for ageing eyes.
The Bottom Line
RYZUMVI is not the end of reading glasses, but it is a notable step in a quiet revolution in how the world treats one of its most common conditions. The trials show a statistically solid benefit over placebo, a familiar side-effect profile dominated by red eye and mild irritation, and a mechanism that differs from the pilocarpine drops already on pharmacy shelves. What remains unanswered is the commercial question — price, coverage and launch timing — and the human one: whether patients will actually reach for a bottle instead of a pair of specs.
For now, the verdict from the clinic is clear: promising, useful for the right person, and not for everyone. As Hovanesian put it, doctors debate, but patients decide. Millions of squinting adults are about to get their say.
